The global hyaluronic acid market was estimated at USD 8.94 billion in 2021 and it is expected to surpass around USD 17.2 billion by 2030, poised to grow at a CAGR of 7.54% from 2022 to 2030
Report Highlights
Factors, such as increasing concern of population regarding chemicals, desire to get quick and evident results, and shorter recovery time are high impact rendering drivers. The industry is evolving rapidly due to the increasing adoption of aesthetic procedures in developed and developing regions. Increasing the use of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving the compatibility coupled with the growing awareness about anti-aging products is fueling the growth.
The efficacy and evident results of hyaluronic acid-based dermal fillers are attracting this population base. Furthermore, the COVID-19 pandemic has changed the dynamics of many industries, with movement restrictions, social distancing, and revised practices becoming the “new normal.” As the cosmetic industry is gradually resuming its operations, a number of doctors have reported a significant increase in the inquiries for aesthetic surgeries. Moreover, the lockdown has encouraged all professionals to use video-conferencing facilities, which has made people more conscious of their looks. In some cases, it has led people to opt for cosmetic treatments; this is termed the “Zoom Boom” or the “Zoom effect.”
Cosmetic surgeons across the world have witnessed a significant increase in the number of patients as a result of the pandemic, particularly in countries, such as the U.S., Australia, and Japan. North America held the maximum revenue share in 2021. Preference for short-treatment regimens, even though high-priced, and the prevalence of target diseases, such as osteoarthritis, are the key factors attributed to the high share. In 2021, the most lucrative product applications in the North America region were in the form of dermal fillers and viscos supplements for the management of osteoarthritis. Asia Pacific is anticipated to register the fastest CAGR during the forecast period.
The growing geriatric population in China and Japan provide a large customer base for anti-aging products and services. Rising awareness about product applications and efficacy also fuels the demand. In addition, increasing disposable income levels are further supporting the region’s expansion. Europe has undergone impressive changes over the last 2 years. The growing demand is witnessing increasing price competition owing to new entrants. The WHO recently announced the obesity epidemic in the U.K. and Germany. The relationship between the increasing aging population and obesity is a potential driver for the Europe regional sector
Scope of The Report
Report Coverage | Details |
Market Size in 2021 | USD 8.94 billion |
Revenue Forecast by 2030 | USD 17.2 billion |
Growth rate from 2022 to 2030 | CAGR of 7.54% |
Base Year | 2021 |
Forecast Period | 2022 to 2030 |
Segmentation | Application, Region |
Companies Covered | Allergan; Sanofi; Genzyme Corp.; Anika Therapeutics, Inc.; Salix Pharmaceuticals; Seikagaku Corp.; F. Hoffmann-La Roche Ag; Galderma Laboratories L.P.; Zimmer Biomet; Smith & Nephew Plc; Ferring B.V.; Lifecore Biomedical, Llc; HTL Biotechnology; Shiseido Company, Ltd.; Bloomage Biotechnology Corporation Ltd.; LG Life Sciences Ltd (LG Chem.); Maruha Nichiro, Inc. |
Application Insights
On the basis of application, the market is segmented as dermal fillers, Osteoarthritis (OA), ophthalmic, and vesicoureteral reflux. The OA dominated the global industry and accounted for more than 43.7% of the overall revenue in the year 2021. The industry is anticipated to grow on account of an increase in the geriatric population and a rising preference for minimally invasive procedures. Almost 90% of prescriptions of viscosupplements are intended for the treatment of knee osteoarthritis. As per the Osteoarthritis Research Society International (OARSI), the U.S., both corticosteroids and hyaluronic acid injections can be used for the treatment of osteoarthritis, but viscosupplementation is slightly more effective than corticosteroids.
Though the share of painkillers in pain management is high, viscosupplements are gaining popularity as a cure. The use of hyaluronan as a treatment for osteoarthritis has been approved by the U.S. FDA in 1997 and has gained substantial industry share. The osteoarthritis segment is further classified into five-injection, three-injection, and single injections. The single hyaluronic acid injection is well received by the market despite higher treatment costs compared to its counterparts. Single injection offers higher convenience and reduces the number of hospital visits while reducing pain and adverse effects.
The increasing geriatric population and rising cases of obesity are further expected to boost the industry growth over the forecast period. According to the American Society of Plastic Surgeons (ASAPS), dermal fillers are the most popular and nonsurgical injectable procedures, especially used for correcting soft tissue defects on the face. Hyaluronic acid-based dermal fillers are commonly used for aesthetic procedures, such as improving nasolabial folds, eye wrinkles, dark circles, scar remediation, and rejuvenation. Hyaluronic acid injections are easy to use, effective, and relatively less expensive, and these associated advantages are expected to drive growth during the forecast period.
Regional Insights
On the basis of geographies, the global industry has been further segmented into North America, Asia Pacific, Middle East & Africa, Europe, and Latin America. North America dominated the global industry in 2021 and accounted for the largest share of more than 43.04% of the overall revenue. This is due to the presence of a sizeable base of the geriatric population, which is more susceptible to disorders, such as osteoarthritis, vesicoureteral reflux, and cataracts. Moreover, the growing demand for minimally invasive cosmetic surgeries is a significant factor contributing to the large share of North America.
Due to the presence of high unmet medical needs in emerging economies, such as South Korea and China, growing awareness about applications of minimally invasive techniques, and increasing disposable income, the Asia Pacific region is expected to register the fastest CAGR during the forecast period. The growing geriatric population in China and Japan provide a large customer base for anti-aging products and services. Increasing awareness about the applications of hyaluronan and its efficacy fuels the demand. Moreover, the Asian population is influenced by western beauty standards and targets volumized appearance. This has resulted in the growth of the regional sector.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1.Research Objective
1.2.Scope of the Study
1.3.Definition
Chapter 2. Research Methodology
2.1.Research Approach
2.2.Data Sources
2.3.Assumptions & Limitations
Chapter 3. Executive Summary
3.1.Market Snapshot
Chapter 4. Market Variables and Scope
4.1.Introduction
4.2.Market Classification and Scope
4.3.Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5.COVID 19 Impact on Hyaluronic Acid Market
5.1. COVID-19 Landscape: Hyaluronic Acid Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4.Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1.Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2.Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1.List of Suppliers
7.1.3.2.List of Buyers
Chapter 8. Global Hyaluronic Acid Market, By Application
8.1.Hyaluronic Acid Market, by Application Type, 2020-2027
8.1.1. Dermal fillers
8.1.1.1.Market Revenue and Forecast (2016-2027)
8.1.2. Osteoarthritis
8.1.2.1.Market Revenue and Forecast (2016-2027)
8.1.3. Ophthalmic
8.1.3.1.Market Revenue and Forecast (2016-2027)
8.1.4. Vesicoureteral reflux
8.1.4.1.Market Revenue and Forecast (2016-2027)
Chapter 9. Global Hyaluronic Acid Market, Regional Estimates and Trend Forecast
9.1.North America
9.1.1. Market Revenue and Forecast, by Application (2016-2027)
9.1.2. U.S.
9.1.3. Rest of North America
9.1.3.1.Market Revenue and Forecast, by Application (2016-2027)
9.2.Europe
9.2.1. Market Revenue and Forecast, by Application (2016-2027)
9.2.2. UK
9.2.2.1.Market Revenue and Forecast, by Application (2016-2027)
9.2.3. France
9.2.3.1.Market Revenue and Forecast, by Application (2016-2027)
9.2.4. Rest of Europe
9.2.4.1.Market Revenue and Forecast, by Application (2016-2027)
Chapter 10.Company Profiles
10.1.Allergan
10.1.1.Company Overview
10.1.2.Product Offerings
10.1.3.Financial Performance
10.1.4.Recent Initiatives
10.2.Sanofi
10.2.1.Company Overview
10.2.2.Product Offerings
10.2.3.Financial Performance
10.2.4.Recent Initiatives
10.3.Genzyme Corporation
10.3.1.Company Overview
10.3.2.Product Offerings
10.3.3.Financial Performance
10.3.4.Recent Initiatives
10.4.Anika Therapeutics, Inc.
10.4.1.Company Overview
10.4.2.Product Offerings
10.4.3.Financial Performance
10.4.4.Recent Initiatives
10.5.Salix Pharmaceuticals
10.5.1.Company Overview
10.5.2.Product Offerings
10.5.3.Financial Performance
10.5.4.Recent Initiatives
10.6.Seikagaku Corporation
10.6.1.Company Overview
10.6.2.Product Offerings
10.6.3.Financial Performance
10.6.4.Recent Initiatives
10.7.F. Hoffmann-La Roche Ag
10.7.1.Company Overview
10.7.2.Product Offerings
10.7.3.Financial Performance
10.7.4.Recent Initiatives
10.8.Galderma Laboratories L.P.
10.8.1.Company Overview
10.8.2.Product Offerings
10.8.3.Financial Performance
10.8.4.Recent Initiatives
10.9.Zimmer Biomet
10.9.1.Company Overview
10.9.2.Product Offerings
10.9.3.Financial Performance
10.9.4.Recent Initiatives
10.10.Smith & Nephew Plc
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11.Research Methodology
11.1.Primary Research
11.2.Secondary Research
11.3.Assumptions
Chapter 12.Appendix
12.1.About Us
12.2.Glossary of Terms